Key findings from Phase 2b trials are guiding the development of a functional cure approach for Hepatitis B Virus (HBV), with more results anticipated in the second half of 2026. Promising developments in discovery programs are gaining traction, notably the mRNA cancer vaccine BRII-5395 advancing to clinical assessment for Hepatocellular Carcinoma (HCC). The company's robust financial standing enables sustained strategic progress.